JP2016522176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522176A5 JP2016522176A5 JP2016509031A JP2016509031A JP2016522176A5 JP 2016522176 A5 JP2016522176 A5 JP 2016522176A5 JP 2016509031 A JP2016509031 A JP 2016509031A JP 2016509031 A JP2016509031 A JP 2016509031A JP 2016522176 A5 JP2016522176 A5 JP 2016522176A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pertuzumab
- variant
- amount
- unpaired cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 43
- 229960002087 pertuzumab Drugs 0.000 claims 37
- 235000018417 cysteine Nutrition 0.000 claims 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 19
- 239000013628 high molecular weight specie Substances 0.000 claims 11
- 239000013627 low molecular weight specie Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000012801 analytical assay Methods 0.000 claims 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000005251 capillar electrophoresis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361812603P | 2013-04-16 | 2013-04-16 | |
| US61/812,603 | 2013-04-16 | ||
| PCT/US2014/034200 WO2014172371A2 (en) | 2013-04-16 | 2014-04-15 | Pertuzumab variants and evaluation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129841A Division JP2020015719A (ja) | 2013-04-16 | 2019-07-12 | ペルツズマブ変異体及びその評価 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522176A JP2016522176A (ja) | 2016-07-28 |
| JP2016522176A5 true JP2016522176A5 (enExample) | 2017-06-01 |
Family
ID=50694078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509031A Withdrawn JP2016522176A (ja) | 2013-04-16 | 2014-04-15 | ペルツズマブ変異体及びその評価 |
| JP2019129841A Pending JP2020015719A (ja) | 2013-04-16 | 2019-07-12 | ペルツズマブ変異体及びその評価 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129841A Pending JP2020015719A (ja) | 2013-04-16 | 2019-07-12 | ペルツズマブ変異体及びその評価 |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US9815904B2 (enExample) |
| EP (3) | EP2986643A2 (enExample) |
| JP (2) | JP2016522176A (enExample) |
| KR (2) | KR20200085942A (enExample) |
| CN (1) | CN105121471A (enExample) |
| AR (1) | AR095863A1 (enExample) |
| AU (3) | AU2014254086B2 (enExample) |
| BR (1) | BR112015024926A2 (enExample) |
| CA (2) | CA2907776C (enExample) |
| CL (3) | CL2015003049A1 (enExample) |
| CR (1) | CR20150576A (enExample) |
| EA (1) | EA201591643A1 (enExample) |
| HK (1) | HK1211948A1 (enExample) |
| IL (2) | IL241103B (enExample) |
| MA (1) | MA38567A1 (enExample) |
| MX (2) | MX368259B (enExample) |
| MY (1) | MY173295A (enExample) |
| NZ (2) | NZ751877A (enExample) |
| PE (2) | PE20151769A1 (enExample) |
| PH (1) | PH12015502382A1 (enExample) |
| RU (2) | RU2019115089A (enExample) |
| SG (3) | SG10201911353WA (enExample) |
| TW (1) | TWI554284B (enExample) |
| WO (1) | WO2014172371A2 (enExample) |
| ZA (1) | ZA201506594B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| KR102223417B1 (ko) | 2009-10-26 | 2021-03-05 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
| MA38567A1 (fr) | 2013-04-16 | 2017-09-29 | Genentech Inc | Variantes de pertuzumab et leur évaluation |
| EP3562844A1 (en) * | 2016-12-28 | 2019-11-06 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| CA3047349C (en) | 2017-01-17 | 2020-09-22 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
| LT3589661T (lt) | 2017-03-02 | 2024-02-12 | Genentech, Inc. | Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas |
| CN110536969A (zh) * | 2017-04-24 | 2019-12-03 | 豪夫迈·罗氏有限公司 | 跨膜或近膜域中的erbb2/her2突变 |
| US20200271663A1 (en) * | 2017-09-13 | 2020-08-27 | Mayo Foundation For Medical Education And Research | Identification and monitoring of acid hydrolysis products of immunoglobulin heavy chains |
| JP7259778B2 (ja) | 2020-01-31 | 2023-04-18 | トヨタ自動車株式会社 | 車両、及び自動運転システム |
| EP3892989A1 (en) * | 2020-04-07 | 2021-10-13 | Ares Trading S.A. | Capillary gel electrophoresis and its use with complex biological molecules |
| EP4171748A1 (en) | 2020-06-29 | 2023-05-03 | Genentech, Inc. | Pertuzumab plus trastuzumab fixed dose combination |
| EP4190818A4 (en) * | 2020-07-28 | 2024-08-07 | Bio-Thera Solutions, Ltd. | ANTI-HER2 ANTIBODY AND ITS USE |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| CN117241833A (zh) | 2021-04-29 | 2023-12-15 | 上海汇连生物医药有限公司 | 抗体偶联药物的制备方法及应用 |
| KR102511384B1 (ko) | 2022-04-14 | 2023-03-16 | 지용환 | 곡물의 손상을 줄일 수 있는 도정기 |
| WO2025021118A1 (zh) * | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | 配体-药物偶联物及其偶联连接子 |
| GB202313175D0 (en) | 2023-08-30 | 2023-10-11 | Univ Oxford Innovation Ltd | A bivalent polypeptide scaffold and uses thereof |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| ES2335365T3 (es) | 1996-11-27 | 2010-03-25 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina a. |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| DK1064027T3 (da) | 1998-03-27 | 2008-09-08 | Genentech Inc | APO-2 Ligand-anti-her-2-antistofsynergier |
| AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| JP5623681B2 (ja) | 1999-05-14 | 2014-11-12 | ジェネンテック， インコーポレイテッド | 抗−ＥｒｂＢ２抗体による治療 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| JP4579471B2 (ja) | 1999-06-25 | 2010-11-10 | ジェネンテック， インコーポレイテッド | 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置 |
| US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| KR20110008112A (ko) | 1999-08-27 | 2011-01-25 | 제넨테크, 인크. | 항-ＥｒｂＢ2 항체 투여 치료 방법 |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US20200048362A1 (en) | 2000-03-16 | 2020-02-13 | Immunogen, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| CN109395082A (zh) | 2000-05-19 | 2019-03-01 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| ATE337395T1 (de) * | 2001-02-07 | 2006-09-15 | Wilex Ag | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper |
| DK1501856T3 (da) | 2002-04-10 | 2013-03-25 | Genentech Inc | Anti-HER2 antistofvarianter |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| DK2263691T3 (da) | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
| LT1543038T (lt) | 2002-09-11 | 2017-07-10 | Genentech, Inc. | Baltymo gryninimas |
| AU2003295798B2 (en) | 2002-11-21 | 2009-09-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
| JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
| HUE029951T2 (en) | 2003-07-28 | 2017-04-28 | Genentech Inc | Reduction of Protein A Dissolution in Protein A Affinity Chromatography |
| JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| KR20070038557A (ko) * | 2004-07-22 | 2007-04-10 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0518086A (pt) | 2004-12-07 | 2008-10-28 | Genentech Inc | métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação |
| AU2005315912A1 (en) | 2004-12-13 | 2006-06-22 | F. Hoffmann-La Roche Ag | Novel pharmaceutical composition containing at least one Dolastatin 10 derivative |
| BRPI0518104B8 (pt) | 2005-01-21 | 2021-05-25 | Genentech Inc | artigo industrializado e uso de anticorpo her2 |
| CN101163503B (zh) | 2005-02-23 | 2013-05-08 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| US20060204505A1 (en) | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| WO2007145862A2 (en) | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
| US8015939B2 (en) | 2006-06-30 | 2011-09-13 | Asml Netherlands B.V. | Imprintable medium dispenser |
| US20080050385A1 (en) | 2006-08-21 | 2008-02-28 | Thomas Friess | Tumor therapy with an anti-vegf antibody |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| TWI352199B (en) | 2007-03-02 | 2011-11-11 | Genentech Inc | Predicting response to a her inhibitor |
| UA102994C2 (ru) | 2007-03-22 | 2013-09-10 | Дженентек, Инк. | АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ |
| EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| CA2687819A1 (en) | 2007-06-06 | 2008-12-11 | F.Hoffmann-La Roche Ag | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| CA3006428A1 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| FI3597659T3 (fi) | 2007-07-09 | 2023-05-03 | Genentech Inc | Disulfidisidoksen pelkistymisen estäminen polypeptidien rekombinantin valmistuksen aikana |
| CN101939006B (zh) | 2007-09-12 | 2015-09-16 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法 |
| US8937161B2 (en) * | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| DK2840090T3 (en) | 2007-10-30 | 2018-04-23 | Genentech Inc | Antibody purification by cation exchange chromatography |
| TWI472339B (zh) * | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| CN102065892A (zh) * | 2008-01-30 | 2011-05-18 | 雅培制药有限公司 | 用于使抗体片段结晶的组合物和方法 |
| CA2716670A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| SI2644204T1 (sl) | 2008-03-18 | 2017-08-31 | Genentech, Inc. | Kombinacije konjugata protitelo proti HER2-zdravilo in pertuzumaba |
| US9235334B2 (en) | 2008-05-09 | 2016-01-12 | Genesis Industries, Llc | Managing landbases and machine operations performed thereon |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
| CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR079256A1 (es) | 2009-12-04 | 2012-01-04 | Genentech Inc | Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1 |
| RS54795B1 (sr) * | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| US20140044709A1 (en) | 2010-12-09 | 2014-02-13 | Genentech, Inc. | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2013139260A (ru) * | 2011-01-28 | 2015-03-10 | Нэшнл Рисеч Каунсил Оф Канада | Конструирование иммуноглобулиновых доменов |
| EP2683413A1 (en) | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
| LT4403228T (lt) | 2011-10-14 | 2025-10-27 | Her2 dimerizacijos inhibitoriaus pertuzumabo panaudojimo būdai ir gamybos produktas, į kurio sudėtį jis įeina | |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| CN109939236A (zh) | 2012-06-08 | 2019-06-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
| JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| MA38567A1 (fr) | 2013-04-16 | 2017-09-29 | Genentech Inc | Variantes de pertuzumab et leur évaluation |
| FI3083686T4 (fi) | 2013-12-17 | 2023-05-09 | Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja | |
| RU2725093C2 (ru) | 2014-04-25 | 2020-06-29 | Дженентек, Инк. | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| TW201818940A (zh) | 2016-11-04 | 2018-06-01 | 美商建南德克公司 | Her2陽性乳癌之治療 |
| EP3562844A1 (en) | 2016-12-28 | 2019-11-06 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| CA3047349C (en) | 2017-01-17 | 2020-09-22 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
| LT3589661T (lt) | 2017-03-02 | 2024-02-12 | Genentech, Inc. | Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas |
| CN111246845A (zh) | 2017-10-20 | 2020-06-05 | 生物技术Rna制药有限公司 | 适用于治疗的脂质体rna制剂的制备和储存 |
| EP4171748A1 (en) | 2020-06-29 | 2023-05-03 | Genentech, Inc. | Pertuzumab plus trastuzumab fixed dose combination |
| JP2023533813A (ja) | 2020-07-14 | 2023-08-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 一定用量配合剤のアッセイ |
| IL303502A (en) | 2020-12-11 | 2023-08-01 | Genentech Inc | Combination therapies for treatment of her2 cancer |
| EP4493180A1 (en) | 2022-03-14 | 2025-01-22 | Genentech Inc. | Combination therapies for breast cancer |
-
2014
- 2014-04-15 MA MA38567A patent/MA38567A1/fr unknown
- 2014-04-15 KR KR1020207019835A patent/KR20200085942A/ko not_active Ceased
- 2014-04-15 CN CN201480020921.2A patent/CN105121471A/zh active Pending
- 2014-04-15 EP EP14723656.6A patent/EP2986643A2/en not_active Withdrawn
- 2014-04-15 PE PE2015002163A patent/PE20151769A1/es unknown
- 2014-04-15 RU RU2019115089A patent/RU2019115089A/ru unknown
- 2014-04-15 SG SG10201911353WA patent/SG10201911353WA/en unknown
- 2014-04-15 CA CA2907776A patent/CA2907776C/en active Active
- 2014-04-15 AU AU2014254086A patent/AU2014254086B2/en active Active
- 2014-04-15 HK HK15112673.2A patent/HK1211948A1/xx unknown
- 2014-04-15 SG SG10201706045RA patent/SG10201706045RA/en unknown
- 2014-04-15 EP EP20201975.8A patent/EP3800204A1/en not_active Withdrawn
- 2014-04-15 NZ NZ751877A patent/NZ751877A/en unknown
- 2014-04-15 WO PCT/US2014/034200 patent/WO2014172371A2/en not_active Ceased
- 2014-04-15 AR ARP140101600A patent/AR095863A1/es unknown
- 2014-04-15 US US14/253,038 patent/US9815904B2/en active Active
- 2014-04-15 EP EP24211694.5A patent/EP4483964A3/en active Pending
- 2014-04-15 CA CA3071678A patent/CA3071678A1/en not_active Abandoned
- 2014-04-15 RU RU2015141520A patent/RU2737727C2/ru active
- 2014-04-15 PE PE2021000128A patent/PE20211214A1/es unknown
- 2014-04-15 EA EA201591643A patent/EA201591643A1/ru unknown
- 2014-04-15 MY MYPI2015002532A patent/MY173295A/en unknown
- 2014-04-15 JP JP2016509031A patent/JP2016522176A/ja not_active Withdrawn
- 2014-04-15 KR KR1020157032283A patent/KR20150143649A/ko not_active Ceased
- 2014-04-15 MX MX2015013898A patent/MX368259B/es active IP Right Grant
- 2014-04-15 TW TW103113741A patent/TWI554284B/zh active
- 2014-04-15 BR BR112015024926A patent/BR112015024926A2/pt not_active Application Discontinuation
- 2014-04-15 NZ NZ712012A patent/NZ712012A/en unknown
- 2014-04-15 SG SG11201508536PA patent/SG11201508536PA/en unknown
-
2015
- 2015-09-03 IL IL241103A patent/IL241103B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06594A patent/ZA201506594B/en unknown
- 2015-10-01 MX MX2019005151A patent/MX2019005151A/es unknown
- 2015-10-14 PH PH12015502382A patent/PH12015502382A1/en unknown
- 2015-10-15 CL CL2015003049A patent/CL2015003049A1/es unknown
- 2015-10-15 CR CR20150576A patent/CR20150576A/es unknown
-
2017
- 2017-09-28 CL CL2017002445A patent/CL2017002445A1/es unknown
- 2017-10-19 US US15/788,574 patent/US9969811B2/en active Active
- 2017-10-19 US US15/788,632 patent/US20180037662A1/en not_active Abandoned
- 2017-10-19 US US15/788,598 patent/US20180037661A1/en not_active Abandoned
-
2018
- 2018-10-05 AU AU2018241141A patent/AU2018241141B2/en active Active
-
2019
- 2019-07-12 US US16/510,287 patent/US20190345258A1/en not_active Abandoned
- 2019-07-12 JP JP2019129841A patent/JP2020015719A/ja active Pending
- 2019-08-06 US US16/533,488 patent/US20200157238A1/en not_active Abandoned
- 2019-08-08 CL CL2019002244A patent/CL2019002244A1/es unknown
- 2019-10-22 AU AU2019253804A patent/AU2019253804A1/en not_active Abandoned
-
2020
- 2020-06-15 IL IL275398A patent/IL275398A/en unknown
-
2022
- 2022-06-27 US US17/809,098 patent/US12145998B2/en active Active
-
2024
- 2024-10-14 US US18/914,687 patent/US20250084181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522176A5 (enExample) | ||
| RU2015141520A (ru) | Варианты пертузумаба и их аналитическая характеристика | |
| US11208498B2 (en) | Treatment and prevention of cancer using HER3 antigen-binding molecules | |
| US20240092937A1 (en) | Her3 antigen-binding molecules | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| CN107847595A (zh) | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 | |
| UA117294C2 (uk) | Імунокон'югат | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
| IL321119A (en) | Glycosylated antibodies | |
| UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
| JP6033459B2 (ja) | Ｂｍｐ−６抗体 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| MX2025002112A (es) | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| EP3283111A1 (en) | Biomarkers related to treatment of cancer with her3 and egfr inhibitors | |
| BR112022010361A2 (pt) | Anticorpos biespecíficos com cisteínas de intercadeias combinadas alternativamente e usos dos mesmos | |
| WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
| JP2019531254A5 (enExample) | ||
| RU2021130292A (ru) | Антитела, специфичные к btn2, и их применение | |
| CY1116848T1 (el) | Πολυνουκλεοτιδια που κωδικευουν νεα pcsk9 παραλλαγματα |